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Online advertising and marketing claims by
providers of proton beam therapy: are they
guideline-based?
Mark T. Corkum1, Wei Liu1, David A. Palma1, Glenn S. Bauman1, Robert E. Dinniwell1, Andrew Warner1,
Mark V. Mishra3 and Alexander V. Louie1,2*
Abstract
Background: Cancer patients frequently search the Internet for treatment options, and hospital websites are seen
as reliable sources of knowledge. Guidelines support the use of proton radiotherapy in specific disease sites or on
clinical trials. This study aims to evaluate direct-to-consumer advertising content and claims made by proton
therapy centre (PTC) websites worldwide.
Methods: Operational PTC websites in English were identified through the Particle Therapy Co-Operative Group
website. Data abstraction of website content was performed independently by two investigators. Eight international
guidelines were consulted to determine guideline-based indications for proton radiotherapy. Univariate and
multivariate logistic regression models were used to determine the characteristics of PTC websites that indicated
proton radiotherapy offered greater disease control or cure rates.
Results: Forty-eight PTCs with 46 English websites were identified. 60·9% of PTC websites claimed proton
therapy provided improved disease control or cure. U.S. websites listed more indications than international
websites (15·5 ± 5·4 vs. 10·4 ± 5·8, p = 0·004). The most common disease sites advertised were prostate (87·0%),
head and neck (87·0%) and pediatrics (82·6%), all of which were indicated in least one international guideline.
Several disease sites advertised were not present in any consensus guidelines, including pancreatobiliary
(52·2%), breast (50·0%), and esophageal (43·5%) cancers. Multivariate analysis found increasing number of
disease sites and claiming their centre was a local or regional leader in proton radiotherapy was associated
with indicating proton radiotherapy offers greater disease control or cure.
Conclusions: Information from PTC websites often differs from recommendations found in international
consensus guidelines. As online marketing information may have significant influence on patient decision-
making, alignment of such information with accepted guidelines and consensus opinion should be adopted
by PTC providers.
Background
The internet is a widely accessed source of medical infor-
mation for patients [1–8]. Direct-to-consumer advertising
(DTCA) on hospital and healthcare organization websites
is common [9], however frequently do not adequately sup-
port their claims with reference to available evidence [10].
While print and broadcast media must conform to nation-
ally regulated standards, there is currently no regulation of
DTCA by healthcare websites despite potential conflict of
interests [3, 10, 11].
Controversial DTCA for new oncology treatments has
been previously identified [9, 12]. Patients with cancer
may be especially vulnerable to controversial marketing
due to associated fear and anxiety [11, 13]. As cancer pa-
tients may place more confidence in online information
when endorsed by professional bodies and organizations
[3, 9], it has been argued that strict guidelines and more
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oversight should be implemented for marketing by can-
cer centres to patients with cancer [9–11, 13].
Proton beam therapy (PBT) is a rapidly emerging tech-
nology with desirable dosimetric advantages compared
to traditional photon radiotherapy (RT). PBT takes ad-
vantage of the “Bragg peak”, allowing for deposition of
radiation to a tumour target with minimal to no exit
dose affecting normal tissues beyond. Routine adoption
of proton beam therapy faces several challenges. High
capital and operating costs create barriers to institutional
and individual patient access to PBT [14], particularly as
insurers may be reluctant to cover treatments where
there is an insufficient evidence base to justify higher
cost PBT compared to lower cost alternatives [15, 16].
Despite these barriers, utilization of PBT is increasing
[17], mirroring the rapid rise in number of PBT centres
worldwide. Controversial online advertising practices
with PBT have previously been identified, targeted
towards men with prostate cancer [18]. International
published guidelines only recommend PBT for a limited
number of disease sites [19–27].
While heavy ion radiotherapy dates as far back as the
1930’s, it was only after Loma Linda opened a three-
gantry facility in 1990 that the number of PBT centres
began to rise rapidly [28]. As of September 2016, there
were 62 operating PBT internationally, including 25 in
the United States, 11 in Japan, and 6 in Germany [29].
There are 37 additional PBT centres under construction
around the world [30]. Business models for PBT differ
across these jurisdictions and ultimately, regardless of
payer, such facilities become economically viable only
when there are sufficient patient volumes to fully utilize
such facilities. The purpose of our study was to compare
DTCA content and claims on proton therapy centre
(PTC) websites against current evidence based indications
(as reflected in published guidelines) to characterize the




All operating PTCs worldwide as of September 1, 2016
were identified on the Particle Therapy Co-operative
Group website (https://www.ptcog.ch/). The website of
each centre was reviewed to confirm its operational sta-
tus. We excluded PTCs without an English website and
three centres that solely treat ocular tumours, as they
lack sufficient energy to treat deeper tumours. The
websites of facilities under construction and facilities in
planning stage identified by the Particle Therapy
Co-operative Group were then reviewed and one add-
itional operational centre was identified. A separate
Internet search did not reveal any additional centres. We
also searched the websites of the five PBT manufacturers
with centres in the United States to confirm that our list
of PTCs was complete. Our final study population con-
sisted of forty-eight operational PTCs and forty-six PTC
websites.
Data collection
The websites of PTCs were evaluated using a standard-
ized data collection form, adapted from previously pub-
lished studies assessing hospital website DTCA [9, 12].
The data collection form is available in Additional file 1:
Appendix A. In two instances, two PTC’s were repre-
sented by a single website; data was collected once for
these PTCs. Data was collected independently by two in-
vestigators (MC and WL), with discrepancies reached by
consensus after further review of the websites and dis-
cussion with a third investigator (AVL).
We evaluated for advertising prominence and compli-
ance with the American Medical Association Opinion
on Advertising and Publicity [31, 32]. Data collected
from each centre’s website included: disease sites that
were claimed to be treatable with PBT, whether PBT
was available as a clinical trial and details regarding ac-
cessibility (cost, travel). Data regarding claims of efficacy,
decreased morbidity, and/or comparisons between PBT
and RT were also collected. Website traffic was evalu-
ated using Alexa Rank (http://www.alexa.com) [33].
Population estimates for the region served by the PBT
centre were obtained from Population Explorer (https://
populationexplorer.com), an international tool developed
by Kimetrica for the U.S. Agency for International
Development’s Famine Early Warning System Network.
Academic practices were defined as those associated
with a medical school and/or residency training pro-
gram; where doubt existed, supplemental internet
searches were performed to clarify.
Eight international guidelines were consulted to deter-
mine disease sites potentially suitable for treatment with
proton radiotherapy [19–27]. According to these guide-
lines, disease sites that were definitely or potentially
indicated for PBT by two or more guidelines included:
pediatric, eye/orbit, benign central nervous system
(CNS), low-grade glioma, other CNS (e.g. spine/bone,
base of skull), liver, head and neck, lymphoma, sarcomas
and recurrent disease. Four disease sites (palliative treat-
ments, prostate, lung and bone cancers) were only
mentioned by a single guideline, and were included in
our study as indicated sites. If a website listed more
generic terms (e.g. glioma instead of low-grade glioma,
base of skull or spine tumour instead of chordoma/
chondrosarcoma, etc.), it was included as a potentially
indicated PBT despite the possibility this could include
non-indicated diagnoses. All other disease sites collected
were considered not to be endorsed by the consensus
international guidelines for PBT treatment.
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Statistical analysis
Descriptive statistics were generated for all websites and
compared between those advertised in the U.S. versus
internationally using the chi-square test, Fisher’s exact
test, two-sample T-test or Wilcoxon rank sum test as ap-
propriate. Where more than one PTC was represented
by a single website, attempts were made to collect separ-
ate demographic data and report it separately. For vari-
ables analyzed at a website level, data were not counted
multiple times. This study was written to meet require-
ments published within the STROBE statement [34].
Univariate and multivariate logistic regression was per-
formed to identify characteristics of websites that were
predictive of greater disease control or cure rates.
Explanatory variables included in the univariate logistic re-
gression analyses were determined a priori. Multivariate
logistic regression initially included univariate variables
with a p-value < 0.10 for each end point. These variables
were sequentially removed using backward elimination
until all remaining covariates had p-values < 0.05. To
allow multivariate analysis for websites representing two
centres, we chose to include demographic data from the
PTC with the greatest surrounding population. All statis-
tical analysis was performed using SAS version 9.4 soft-
ware (SAS institute, Cary NC), using two-sided statistical
testing at the 0.05 significance level.
Results
Forty-eight PTC centres were identified resulting in
forty-six PTC websites for analysis. Additional file 2:
Appendix B summarizes included and excluded PTC’s
including reason for exclusion. Features of included
websites are presented in Table 1. Twenty-four PTCs
(with twenty-two websites) were from the United States,
62.5% were considered academic centres and 47.8% of
webpages listed the manufacturer of their proton treat-
ment machine, of which 45.5% claimed that their
machine was superior. PBT-specific patient testimonials
were present on 43.5% of websites, and 63.0% included a
section dedicated to out-of-town patients. The amount
of information contained within each website varied
greatly, from single webpages only containing general in-
formation to detailed discussions about the merits of
PBT for specific disease sites.
Selected treatable disease sites listed on PTC websites
are presented in Table 2. A full list of disease sites
mentioned on websites is available in Additional file 3:
Appendix C. The mean number of disease sites listed on
all websites was 12.8 ± 6.1, with 15.5 ± 5.4 for U.S. com-
pared to 10.4 ± 5.8 for international (p = 0.004). The most
common disease sites listed on websites were prostate
(87.0%), head and neck (87.0%), and pediatric tumours
(82.6%). Several disease sites advertised were not present
in any international consensus guidelines, including
pancreatobiliary (52.2%), breast (50.0%), esophageal (43.5%),
colorectal (39.1%) and gynecologic (30.4%) cancers.
Several disease sites were more frequently mentioned on
U.S. websites in comparison to international websites,
including spinal (77.3% vs. 41.7%; p = 0.014), anal (36.4% vs.
0%; p= 0.001), colorectal (54.6% vs. 25.0%, p= 0.040), stom-
ach (31.8% vs. 4.2%; p= 0.020), breast (77.3% vs. 25.0%; p
< 0.001), lymphoma (68.2% vs. 16.7%; p < 0.001), lung
(95.5% vs. 58.3%; p= 0.003) and pediatric tumours (95.5%
vs. 70.8%, p= 0.049).
Claims made by PTC websites are presented in Table 3.
Sixty-one percent of websites claimed proton therapy
provided improved disease control or cure, with 13.0%
of websites stating that for at least one disease site PBT
was the standard of care treatment. Sixty-one percent of
websites stated that proton therapy was more effective
Table 1 Information about Proton Therapy Centre Websites
All Websites % (n)
(N = 46 unless
otherwise specified)
Proton Centre Location (N = 48)




Website from an Academic Proton Centre (N = 48) 62.5% (30)
Another Proton Centre within 300 km (N = 48) 52.1% (25)
Population Estimate within 100 km of Proton Centre (N = 48)
≤ 2,499,999 18.8% (9)
2,500,000–4,999,999 25% (12)
5,000,000–9,999,999 20.8% (10)
≥ 10,000,000 35.4% (17)
Number of Clicks to First Page Mentioning Proton Therapy
0 (directly on homepage) 56.5% (26)
1 26.1% (12)
≥ 2 17.4% (8)
Manufacturer of Machine Listed 47.8% (22)
Claim Their Proton Machine Superior (N = 22) 45.5% (10)
Stock Material from Manufacturer Present
(N = 22)
31.8% (7)
Stock Material Acknowledged from
Manufacturer (N = 7)
42.9% (3)
Link to Manufacturer Website Present (N = 22) 13.6% (3)
Number of Clicks to Mention of Manufacturer (N = 22)
0 (directly on homepage) 13.6% (3)
1 40.9% (9)
≥ 2 45.5% (10)
Out-of-Town Patient Section on Website 63.0% (29)
Proton Therapy Patient Testimonials on Website 43.5% (20)
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(i.e. improved survival or local control) than photon RT.
Ninety-eight percent of websites stated there was a dose
distribution advantage to proton therapy: 84.8% stated
fewer side effects, 39.1% stated improved quality-of-life
and 84.8% and 21.7% of websites stated decreased mor-
bidity compared to photon RT and surgery respectively.
Discussion about the cost/insurance coverage of proton
therapy and availability in clinical trial setting was
present in 69.6% and 56.5% respectively.
References were infrequently provided on websites:
4.4% provided references for all claims with 32.6% fur-
ther websites providing a scientific reference for at least
one claim. Seven percent stated that their claims were
backed by scientific studies without a reference whereas
56.5% did not provide any references.
On univariate analysis, increasing number of disease
sites listed (odds ratio (OR) per additional site: 1.14, 95%
confidence interval (CI): 1.02–1.29, p = 0.025) and
claiming to be a local/regional leader in PBT (OR: 4.67,
95% CI: 1.22–17.82, p = 0.024) were predictive of claim-
ing better disease control or cure. Both of these factors
remained significant on multivariate analysis (OR: 1.15,
95% CI: 1.02–1.31, p = 0.027 and OR: 5.15, 95% CI:
1.22–21.80, p = 0.026 respectively).
Discussion
Proton radiotherapy is a rapidly expanding treatment
modality that has attractive dosimetric advantages
compared to photon radiotherapy, albeit at an increased
capital and per-fraction reimbursement costs [14]. The
main findings of this study are that worldwide, PTC
websites commonly contain DTCA for PBT that are fre-
quently not supported by evidence, and often advertise
the treatment of cancer sites not currently endorsed by
international consensus guidelines. This did not appear
to be localized to a single centre, country or disease site;
Table 2 Proportion of Selected Disease Sites Mentioned on Proton Therapy Centre Websites
Site All Websites % (n)(N = 46) US Websites % (n)
(N = 22)




Number of Sites Listed
(mean ± SD) 12.8 ± 6.1 15.5 ± 5.4 10.4 ± 5.8 0.004
Adult CNS (any)* 89.1% (41) 95.5% (21) 83.3% (20) 0.349
Benign 58.7% (27) 63.6% (14) 54.2% (13) 0.515
Glioma (High or Low Grade) 45.7% (21) 50.0% (11) 41.7% (10) 0.571
Other (e.g. base of skull) 65.2% (30) 59.1% (13) 70.8% (17) 0.404
Spine 58.7% (26) 77.3% (17) 41.7% (10) 0.014
Bladder 19.6% (9) 27.3% (6) 12.5% (3) 0.276
Breast 50.0% (23) 77.3% (17) 25.0% (6) < 0.001
Eye/Orbit 58.7% (27) 68.2% (15) 50.0% (12) 0.211
GI (any)* 76.1% (35) 90.9% (20) 62.5% (15) 0.024
Anal 17.4% (8) 36.4% (8) 0% (0) 0.001
Colorectal 39.1% (18) 54.6% (12) 25.0% (6) 0.040
Esophagus 43.5% (20) 54.6% (12) 33.3% (8) 0.147
Liver 56.5% (26) 54.6% (12) 58.3% (14) 0.796
Pancreatobiliary 52.2% (24) 68.2% (15) 37.5% (9) 0.037
Stomach 17.4% (8) 31.8% (7) 4.2% (1) 0.020
Gynecologic 30.4% (14) 36.4% (8) 25.0% (6) 0.403
Head and Neck 87.0% (40) 90.9% (20) 83.3% (20) 0.667
Kidney 13.0% (6) 4.6% (1) 20.8% (5) 0.190
Lymphoma 41.3% (19) 68.2% (15) 16.7% (4) < 0.001
Lung 76.1% (35) 95.5% (21) 58.3% (14) 0.003
Pediatric Tumours 82.6% (38) 95.5% (21) 70.8% (17) 0.049
Prostate 87.0% (40) 95.5% (21) 79.2% (19) 0.190
Recurrent Disease 54.4% (25) 54.6% (12) 54.2% (13) 0.979
Sarcoma 67.4% (31) 81.8% (18) 54.2% (13) 0.046
*These sites contain additional categories not presented, available in Appendix C
All entries with p<0.05 are bolded with italic underline
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rather, this trend exists globally and for a multitude of
cancer sites.
The ethical implications of DTCA within healthcare
are neither new, nor unique to radiation oncology.
Currently, the United States and New Zealand are the
only two countries that permit print and broadcast
DTCA within healthcare [35]; no countries regulate
DTCA from online sources [11]. In the U.S., the Food
and Drug Administration (FDA) regulates print and
broadcast advertising: although only major risk informa-
tion must be disclosed, they must direct consumers to
other accessible sources of information on literature and
all other associated risks [36]. Supporters of DTCA
argue that it increases awareness, education and em-
powerment to facilitate patient-centred decision-making
and decrease paternalistic care [37]. In contrast, argu-
ments against DTCA include the high literacy level re-
quired, bypassing the patient-provider relationship,
overutilization, and increased healthcare costs [37].
Cancer centres producing DTCA for new radiotherapy
technologies was previously questioned with the
introduction of Intensity Modulated Radiation Therapy
(IMRT) to mainstream radiation oncology practices in
the 2000’s [38]. While IMRT implementation was also
questioned due to concerns of tumour targeting and risk
of secondary malignancies (with larger volumes of
normal tissues receiving low dose radiotherapy), the in-
creased costs of IMRT were also a valid concern [39].
While the safety and accuracy of PBT have not been
questioned to the same degree, the increased costs of
PBT surpass those of IMRT, arising from both high
capital costs plus increased reimbursement per fraction
[14]. Traditional multi-room proton facilities cost in
excess of 100 million USD [40], though single-room pro-
ton machines have now entered the market with a lower
capital cost [41, 42]. Recent systematic reviews of the
cost-effectiveness of PBT suggest superiority in several
disease sites, such as particular pediatric brain tumours,
left sided breast cancers at high risk of cardiac toxicity,
selected head and neck cancers, and locally advanced
lung cancers, acknowledging this finding is limited by
the lack of published literature [43, 44].
As cancer care is highly profitable [45], it should not
be surprising that spending on advertising is increasing.
In 2014, $173 million was spent on cancer centre adver-
tising in the U.S., roughly triple the amount compared
to 2005 [46]. Of the 1500 cancer centres in the U.S., 20
accounted for 86% of advertising spending, of which 9
were NCI-designated [46]. Of these 20 centres, five were
included in our study. The advertising practices of cancer
centres have previously been brought into question, includ-
ing appeals to the emotions of a vulnerable patient popula-
tion, hope for survival, and improved outcomes without
supporting factual information, while not mentioning costs
or risks associated with treatment [11, 13, 46–48]. Our study
supports these findings, demonstrating PTC websites fre-
quently offer PBT to non-guideline recommended cancer
sites, contain language which evokes hope for better treat-
ment outcomes, and infrequently support all claims made
on their website.
It has been argued that randomized clinical trials for
PBT are not necessary due to the clear dose distribution
advantages over RT [44, 49]. In addition, it has been
argued that the capacity constraints of PBT centres pre-
cludes the ability to perform randomized clinical trials
[50]. While some side effects are likely to be improved
with PBT, it is possible that certain side effects, such as
skin toxicity, could be expected to be worse with inten-
sity modulated proton therapy [51]. There are over 100
clinical trials underway examining proton radiotherapy,
albeit with only eight randomized clinical trials directly
comparing proton versus photon radiotherapy [52].
Recently, the first presentation of a randomized study
between proton and photon radiotherapy of 147 patients
with locally advanced non-small cell lung cancer was
published in abstract form, finding no difference in
Table 3 Claims Made on Proton Therapy Centre Websites
All Websites % (n)
(N = 46 unless
otherwise specified)
Claims about Proton Therapy
Improved Disease Control or Cure 60.9% (28)
Standard of Care 13.0% (6)
Fewer Side Effects 84.8% (39)
Specific Side Effects Listed 67.4% (31)
Quicker Recovery Time 15.2% (7)
Increased Quality-of-Life 39.1% (18)
Dose Distribution Advantage 97.8% (45)
Claims and comparison to Other Modalities
Photon RT: Increased Efficacy 60.9% (28)
Photon RT: Decreased Morbidity 84.8% (39)
Surgery: Increased Efficacy 2.2% (1)
Surgery: Decreased Morbidity 21.7% (10)
Evidence Provided for Claims on Website
All Claims Referenced 4.4% (2)
Some Claims Referenced 32.6% (15)
Generic References (e.g. Studies show that…) 6.5% (3)
No Claims Referenced 56.5% (26)
Alternative Treatment(s) to Proton Therapy Listed 89.1% (41)
Claim Local/Regional Leader in Proton Therapy 43.5% (20)
Length of Time Treating/Patient Volume Listed 71.7% (33)
Mention of Cost/Insurance of Proton Therapy 69.6% (32)
Proton Therapy as Clinical Trial Listed 56.5% (26)
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treatment failure or ≥ grade 3 radiation pneumonitis be-
tween the two treatment modalities [53].
In the absence of randomized data, we examined 8
guidelines on proton therapy to identify disease sites in-
dicated for PBT [19–27]. These guidelines are from the
U.S., Canada, Australia and New Zealand, the U.K.,
Denmark and the Netherlands. The publication dates
range from 2009 to 2017. Guidelines differ on disease
site indications, therefore when determining disease sites
indicated by guidelines, we used a threshold of at least
one guideline indicating a disease site. After review of
the international guidelines, there were four disease sites
only endorsed by a single guideline (NCCN guidelines).
These four sites (prostate cancer, lung cancer, bone can-
cers and palliative tumours), were considered to be indi-
cated sites for purposes of our study. Prostate cancer
was considered an indicated site despite the NCCN
guideline also clearly stating that “They believe no clear
evidence supports a benefit or decrement to proton therapy
over IMRT for either treatment efficacy or long-term
toxicity” [54]. Despite retrospective and prospective co-
hort studies demonstrating favourable side effect profiles
for PBT in several disease sites not mentioned in these
guidelines (such as pancreas [55], breast [56], esophagus
[57] and cervical [58] cancers), these were not consid-
ered indications in our study as they have not been cited
in guidelines to date, and are subject to bias.
To our knowledge, this is the first systematic evalu-
ation of DTCA on English PTC websites. However, our
data is limited by inconsistencies between how disease
sites were listed in international guidelines and websites.
For example, many websites did not separate high and
low grade gliomas. Several guidelines support the use of
PBT for low grade gliomas [19, 21, 24], but no guidelines
support the use of PBT in high grade gliomas. Other
limitations of our study are excluding ten websites that
were not in English. Several international websites that
did have an English webpage contained limited informa-
tion relative to equivalent U.S. websites. As such, our
data for these websites may not be completely represen-
tative of DTCA towards the primary target audience.
Inclusion of a disease site within a guideline is one
measure of alignment with evidence based care but has
limitations. Guidelines may be limited by the evidence
base available or may be influenced by expert opinion
depending on the methodology used to generate the
guideline. We did not incorporate the availability of pen-
cil beam scanning in our study. Some PTC’s offer both
PBT and carbon ion therapy. At times, it was difficult to
separate claims for PBT and carbon ion therapy. Finally,
the nature of DTCA by an institution does not necessar-
ily reflect the level of discussion that occurs at the
provider/patient level. For example, while an indication
might be listed on a DTCA website, an informed discussion
with the patient may include discussions of alternatives and
tailoring of recommendations to that individual’s situation.
Such provisos that acknowledge treatments need to be indi-
vidualized (“check with your doctor if drug x is right for
you”) are a mainstay of other forms of DTCA but were not
a prominent feature of the websites we examined.
Conclusions
Our study shows that PTC websites contain DTCA for
disease sites that are not endorsed by international con-
sensus guidelines, in addition to appealing to the emo-
tions of patients by often claiming superior disease
control or decreased side effect profiles. This follows the
pattern of other cancer treatments such as robotic sur-
gery for prostate cancer and stereotactic body radiation
therapy. Similar to the early adoption of IMRT radio-
therapy, we postulate that there is a need to balance
rapid adoption of PBT as an emerging technology and
establishing randomized evidence upon which the rec-
ommendation for PBT can be made. The results of this
study highlight the urgent need for comparative effect-
iveness PBT research in order to develop updated and
high-quality evidence-based recommendations that can
be used to inform its judicious use and to generate ap-
propriate informational materials for patients.
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